Symptoms and Endoscopic Results in Consideration of Pretreatment

Completed

• Conditions: Gastrointestinal Diseases

• Registration Number: NCT00612404
• Lead Sponsor: AstraZeneca

Brief Summary

Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. gastroenterologists) are asked to document relevant data in patients with gastrointestinal disorders.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09
• Primary Completion: 2005-12
• Status Verified: 2008-01
• Study First Submitted: 2008-01-28
• Study First Submitted QC: 2008-02-08
• Last Update Submitted: 2008-02-08
• Study First Posted: 2008-02-11
• Last Update Posted: 2008-02-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16255

Inclusion Criteria

• patients with gastrointestinal disorders who need an endoscopy.

Read More

Exclusion Criteria

• limitiations; possible risks; warnings; contraindications mentioned in the SPC.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
to gain insight into the relationship between subjective gastrointestinal symptoms and findings of a laryngopharyngeal-esophagogastric endoscopy with respect to the medicinal pre-therapy;

Secondary Outcome Measures

Name	Time	Method
to gain insight into the currently used treatment strategies with esomeprazole depending on endoscopic findings.